landiolol

Landiolol is a rapid-acting, ultra-short-acting, highly selective beta-1 adrenergic receptor antagonist (beta-blocker) used for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter. It is administered intravenously and has a very short elimination half-life (3–4 minutes), allowing for quick titration and offset of effect. Landiolol decreases heart rate by blocking the positive chronotropic effects of catecholamines (epinephrine and norepinephrine) on cardiac beta-1 receptors without significant negative inotropic or hypotensive effects compared to other beta-blockers. It does not exhibit membrane-stabilizing or intrinsic sympathomimetic activity at recommended doses. First approved in Japan in 2002, it has since been approved in Canada (2023) and the US (2024). Its unique pharmacokinetic profile makes it especially useful when rapid onset/offset of action is required[1][2][5].

Brand names

RapiblykOnoactSibboran

Other names

landiolol hydrochloridelandiolol HCl